Business Wire

CA-DENODO

27.10.2021 09:02:12 CEST | Business Wire | Press release

Share
Denodo Concludes Another Massively Successful Annual User Conference With 5,000 Worldwide Registrants Across North America, EMEA and APAC

Denodo , the leader in data virtualization, today announced that its annual global user conference, Denodo DataFest 2021 , which was held in North America (NA), EMEA and APAC, attracted 5,000 worldwide registrants. While DataFest APAC and EMEA were held in a virtual format this year, DataFest NA was conducted in a hybrid mode, attracting hundreds of attendees online and in-person in New York. The attendees, made up of Denodo customers, partners, and subject matter experts, discussed the future of data and analytics involving topics such as logical data fabric, cloud modernization, data mesh, AI/ML and more.

Forrester VP and Principal Analyst Michele Goetz kicked off the conference presenting the Total Economic Impact™ of Data Virtualization using Denodo Platform , while David Loshin, President of Knowledge Integrity at TDWI presented the importance of Logical Data Fabric for Hybrid Cloud. Click here to watch the full conference line up.

“While we are not entirely over the pandemic yet, I was personally touched and thrilled to see the excitement among our customers and partners, both in-person and online who joined us to make this year’s DataFest such a success,” said Ravi Shankar, SVP and CMO at Denodo. “Our customers, partners, and internal subject matter experts presented and discussed topics such as why data lakehouse needs a logical architecture, application of advanced semantics in multi/hybrid cloud scenarios, the need for performance acceleration for advanced analytics and data science, to name a few. It was great to see the strength of our customers’ use cases as the Innovation Award polling saw stiff competition among the finalists.”

Winners and Finalists of Denodo Data Innovation Awards 2021 include:

  • North America – Winner Ryan Fattini from City Furniture , for their Digitizing City Furniture’s Business Model use case; finalist Jonathan Paul from Fifth Third Bank , for their Digital Transformation and Regulatory Excellence use case.
  • APAC – Winner Shaurya Bhasin from GeTS , for their Logical Data Fabric use case; finalist Wilbertus Darmadi from Toyota Astra Motor , for their Data Catalog based Self-Service use case.
  • EMEA – Winner Jan Swanepoel from NedBank , for their Largest Data Warehouse on the Planet use case; finalist, Luis Guadarrama from Engie for their data-driven initiatives with Logical Data Fabric use case.

“Winning this year’s Data Innovation Award for the APAC region was a great validation of the strength of our data virtualization use cases and the results we were able to achieve,” said Shaurya Bhasin, Data Platform Lead at GeTS. “In building our unified data platform we were able to offer secure and well governed data access in a multi-cloud scenario. The Denodo Platform is as an important piece of the architecture and I was happy to share our story with the DataFest audience and perhaps it resonated with the audience!”

While Denodo customers played a pivotal role in sharing their business and technical use cases with the audience, it was the amazing network of Denodo Partners which included Accenture, Advanced Analytic Service, Axians, BDO (SimplicityBI), BITanium, CIO Academy Asia (CIOAA), Cognizant, Cyberionix, Dai Nippon Printing, DAMA, Devfacto, EY, Hitachi Solutions, Indium Software, Insight Technology, iOCO, IQZ Systems, JEMS, Mainline, MDI Novare Technologies, Nippon Systemware, NS Solutions, Nucleus Software, Q Perior, Servian, Sirius, UST, Wipro and Zeal that made an event of this scale possible. Denodo’s technology partner AWS took part in a Fireside chat to discuss the important of Logical Data Fabric for successful cloud migration.

Please tweet: #datavirtualization leader Denodo announce the winners of 4th annal Data Innovation Awards During #DataFest 2021. Audience vote @CityFurniture, @CLGeTS and @Nedbank for the most innovative use cases

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye